- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call | 1 | Benzinga.com | ||
| 23.09. | TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support | 6 | Benzinga.com | ||
| 23.09. | TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday | 1 | Benzinga.com | ||
| 23.09. | H.C. Wainwright raises TriSalus stock price target on FDA approval | 3 | Investing.com | ||
| 23.09. | TriSalus jumps 16% after FDA clears TriNav Advance device | 1 | Seeking Alpha | ||
| 22.09. | TriSalus Life Sciences: Aktie steigt nach FDA-Zulassung um 29 % | 2 | Investing.com Deutsch | ||
| TRISALUS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 22.09. | TriSalus erhält FDA-Zulassung für das System TriNav Advance | 2 | Investing.com Deutsch | ||
| 22.09. | TriSalus receives FDA clearance for TriNav Advance device | 2 | Investing.com | ||
| 22.09. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | TriSalus Life Sciences GAAP EPS of -$0.16 misses by $0.01, revenue of $11.41M beats by $1.14M | 2 | Seeking Alpha | ||
| 07.08. | Trisalus reiterates 2026 revenue guidance of $54M-$57M as CMS G-code expands TriNav reimbursement into office-based labs | 1 | Seeking Alpha | ||
| 06.08. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Canaccord reiterates TriSalus stock Buy rating after KOL event | 1 | Investing.com | ||
| 18.05. | TriSalus Life Sciences: Aktie steigt trotz Umsatzrückgang im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 13.05. | TriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goal | 1 | Seeking Alpha | ||
| 12.05. | TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 12.05. | TriSalus Life Sciences GAAP EPS of $0.03 beats by $0.19, revenue of $8.9M misses by $1.54M | 2 | Seeking Alpha | ||
| 12.05. | TriSalus senkt Umsatzprognose für 2026 auf 54-57 Mio. US-Dollar | 3 | Investing.com Deutsch | ||
| 12.05. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 15,726 | -0,09 % | Viatris Inc.: Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies | Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International... ► Artikel lesen | |
| SYNBIOTIC | 0,759 | -0,26 % | Viome Acquires Solaria Bio To Expand Into Clinically Validated Synbiotics And Medical Foods | ||
| ORGANIGRAM GLOBAL | 0,832 | -0,36 % | Organigram Global Inc.: Organigram Global treibt die Integration der Sanity Group unter einer einheitlichen globalen Betriebsstruktur voran | Führung, operatives Geschäft und Marktentwicklung werden über eine globale Plattform aufeinander abgestimmt, die Kanada mit Deutschland und anderen wichtigen internationalen Märkten verbindet
Die... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 5,994 | +0,77 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA | New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,795 | 0,00 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,750 | +0,47 % | TOP-MELDUNG bei SELLAS Life Sciences Group Inc: Startet die Aktie jetzt die große Rallye? - Mein Rat: sofort handeln! | ||
| OPKO HEALTH | 1,210 | -2,42 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,542 | +0,53 % | XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why | ||
| SOLIGENIX | 0,354 | +0,51 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| OPUS GENETICS | 4,300 | +2,87 % | Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff? | ||
| TALPHERA | 0,940 | -3,59 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,599 | +6,09 % | Citizens reiterates Savara stock rating on Molbreevi launch outlook | ||
| SCYNEXIS | 3,625 | 0,00 % | SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | • SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated • Phase 2 proof-of-concept study in patients with ADPKD remains... ► Artikel lesen | |
| PROTHENA | 7,988 | +5,49 % | Prothena Corporation plc: Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 3,040 | +3,40 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD | Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing)... ► Artikel lesen |
Das Unternehmen TRISALUS LIFE SCIENCES INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRISALUS LIFE SCIENCES INC finden Sie auf Wallstreet Online.